Abstract |
Adult T cell leukemia/lymphoma ( ATLL) induced by human T cell leukemia virus I is resistant to conventional therapy. Six patients with ATLL were treated with a new antitumor agent, MST-16, which is a derivative of bis(2,6-dioxopiperazine). Two patients achieved complete remission, lasting 12 months and more than 8 months, and 2 others partial remission, lasting 2 months and 6 weeks, respectively. The major toxicity was myelosuppression. Other toxicities were not severe and were well tolerable. Orally administered MST-16 is a promising agent for the treatment of ATLL.
|
Authors | T Ichihashi, H Kiyoi, H Fukutani, K Kubo, T Yamauchi, T Naoe, K Yamada, R Ohno |
Journal | Oncology
(Oncology)
Vol. 49
Issue 5
Pg. 333-5
( 1992)
ISSN: 0030-2414 [Print] Switzerland |
PMID | 1528567
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Piperazines
- sobuzoxane
|
Topics |
- Administration, Oral
- Adult
- Aged
- Antineoplastic Agents
(therapeutic use)
- Drug Evaluation
- Female
- Humans
- Leukemia-Lymphoma, Adult T-Cell
(drug therapy)
- Male
- Piperazines
(administration & dosage)
|